Replies to post #3697 on GTC Biotherapeutics (fka GTCB)

[genisi]

Inhaled Alpha-1 Antitrypsin - Kamada
In a conference I attended on May, David Tsur kamada's CEO said that they already know that the inhaled dose is about 25% of the injectable one. Given the limitation of plasma supply, these are good news.
If efficacy will work fine, they will try the inhaled delivery for other indications such as Cistic Fibrosis which suppose to be more profitable.